Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer

JCO Precis Oncol. 2021 Nov:5:1082-1087. doi: 10.1200/PO.21.00107.

Authors

Dilara Akhoundova¹, Heike Pietge¹, Saskia Hussung¹, Michael Kiessling¹, Christian Britschgi¹, Martin Zoche², Markus Rechsteiner², Achim Weber², Ralph M Fritsch¹

Affiliations

¹ Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland.
² Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland.

PMID: 34994629
DOI: 10.1200/PO.21.00107

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics
Colorectal Neoplasms / pathology
Drug Resistance, Neoplasm
Humans
Male
Mutation
Neoplasm Metastasis / genetics
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / genetics

Substances

BRAF protein, human
Proto-Oncogene Proteins B-raf